Replies to post #9200 on Ayala Pharmaceuticals Inc (ADXS)

[equaloppforall]

My understanding, based on clinicaltrials.gov updates, is that ADXS is screening patients at multiple sites for enrollment into P3 AXAL trials but has yet to dose the first patient. My hunch is that they are more likely than not to initiate dosing after they sign up with a US and European partner. Let us see how it unfolds.